WO2005115869A1 - Medicament housing apparatus having outer and inner containers - Google Patents
Medicament housing apparatus having outer and inner containers Download PDFInfo
- Publication number
- WO2005115869A1 WO2005115869A1 PCT/US2005/017027 US2005017027W WO2005115869A1 WO 2005115869 A1 WO2005115869 A1 WO 2005115869A1 US 2005017027 W US2005017027 W US 2005017027W WO 2005115869 A1 WO2005115869 A1 WO 2005115869A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- container
- packaging system
- outer container
- inner container
- medicaments
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims description 42
- 238000004806 packaging method and process Methods 0.000 claims abstract description 50
- 239000011800 void material Substances 0.000 claims abstract description 10
- -1 polypropylene Polymers 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 7
- 229920000642 polymer Polymers 0.000 claims description 6
- 239000004698 Polyethylene Substances 0.000 claims description 3
- 239000004743 Polypropylene Substances 0.000 claims description 3
- 229920001328 Polyvinylidene chloride Polymers 0.000 claims description 3
- 239000000556 agonist Substances 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 230000001093 anti-cancer Effects 0.000 claims description 3
- 229940088710 antibiotic agent Drugs 0.000 claims description 3
- 239000003443 antiviral agent Substances 0.000 claims description 3
- 229940121357 antivirals Drugs 0.000 claims description 3
- 210000003169 central nervous system Anatomy 0.000 claims description 3
- 229940111134 coxibs Drugs 0.000 claims description 3
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims description 3
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 3
- 230000002503 metabolic effect Effects 0.000 claims description 3
- 230000000926 neurological effect Effects 0.000 claims description 3
- 229920002493 poly(chlorotrifluoroethylene) Polymers 0.000 claims description 3
- 239000005023 polychlorotrifluoroethylene (PCTFE) polymer Substances 0.000 claims description 3
- 229920000573 polyethylene Polymers 0.000 claims description 3
- 229920001155 polypropylene Polymers 0.000 claims description 3
- 229920000915 polyvinyl chloride Polymers 0.000 claims description 3
- 239000004800 polyvinyl chloride Substances 0.000 claims description 3
- 239000005033 polyvinylidene chloride Substances 0.000 claims description 3
- 239000002464 receptor antagonist Substances 0.000 claims description 3
- 229940044551 receptor antagonist Drugs 0.000 claims description 3
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 claims description 3
- 208000005176 Hepatitis C Diseases 0.000 claims 2
- 208000002672 hepatitis B Diseases 0.000 claims 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000008203 oral pharmaceutical composition Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004377 microelectronic Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical class [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D23/00—Details of bottles or jars not otherwise provided for
- B65D23/12—Means for the attachment of smaller articles
- B65D23/14—Means for the attachment of smaller articles of tags, labels, cards, coupons, decorations or the like
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D1/00—Containers having bodies formed in one piece, e.g. by casting metallic material, by moulding plastics, by blowing vitreous material, by throwing ceramic material, by moulding pulped fibrous material, by deep-drawing operations performed on sheet material
- B65D1/02—Bottles or similar containers with necks or like restricted apertures, designed for pouring contents
- B65D1/0223—Bottles or similar containers with necks or like restricted apertures, designed for pouring contents characterised by shape
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D11/00—Containers having bodies formed by interconnecting or uniting two or more rigid, or substantially rigid, components made wholly or mainly of plastics material
- B65D11/16—Containers having bodies formed by interconnecting or uniting two or more rigid, or substantially rigid, components made wholly or mainly of plastics material with double walls
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D2203/00—Decoration means, markings, information elements, contents indicators
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D2203/00—Decoration means, markings, information elements, contents indicators
- B65D2203/10—Transponders
Definitions
- the invention generally relates to packaging for housing medicament.
- packaging pharmaceutical medicament present in oral dosage form are disclosed. Specific examples include those intended to accommodate packaging a variety of predetermined volumes of medicament.
- U.S. Patent Nos. 5,315,81 1 ; 5,197,602; and 6,243,936 disclose packaging systems for containing materials therein, and methods for assembling packaging systems for containing materials. Notwithstanding any potential advantages offered by the above- proposed packaging systems, such systems may be potentially complicated from an assembling perspective in that an individual packaging system is made up of multiple components. It would be desirable to obtain a packaging system that is simpler in structure, thus having the potential to reduce multiple steps in assembling a conventional packaging system.
- the present invention provides a packaging system.
- the packaging system includes a plurality of substantially uniformly shaped containers comprising an outer container and an inner container present within the outer container.
- the outer container includes a flange and a container wall attached thereto and extending downwardly from the flange.
- the inner container includes a container wall and a bottom portion attached to the container wall which closes the inner container. Both the outer container and the inner container each have respective cross-sections.
- the outer container has a bottom portion that is not enclosed, and a void space is present between the outer container and the inner container.
- the inner container further includes a neck having a base portion and wherein the flange of said outer container is attached to the base portion.
- FIGS. 1a and 1b respectively are side and bottom cross-sectional views of an embodiment of the packaging system.
- FIG. 2 is a perspective view of an embodiment of the packaging system.
- FIGS. 3a and 3b respectively are side and bottom cross-sectional views of an embodiment of the packaging system.
- FIG. 4 is a perspective view of an embodiment of the packaging system.
- FIG. 5 is a perspective view of an embodiment of an array of packaging systems.
- a number of materials may be employed in forming the outer and inner containers of the invention.
- these may be formed from a polymer, preferably one or more thermoplastic polymers.
- Exemplary polymers include at least one material such as, without limitation, polyvinyl chloride, polyvinylidene chloride, polypropylene, polyethylene, polychlorotrifluoroethylene, and combinations thereof.
- the packaging system of the present invention may be fabricated by employed accepted techniques such as, without limitation, injection molding. At least one medicament may be housed in the packaging system of the present invention.
- the term “medicament”, as used herein, is meant to mean and include any substance (i.e., compound or composition of matter) which, when administered to an organism (human or animal) induces a desired pharmacologic and/or physiologic effect by local and/or systemic action.
- the term therefore encompasses substances traditionally regarded as actives, drugs and bioactive agents, as well as biopharmaceuticals (e.g., peptides, hormones, nucleic acids, gene constructs, etc.) typically employed to treat a number of conditions which is defined broadly to encompass diseases, disorders, infections, and the like.
- Exemplary medicaments include, without limitation, antibiotics, antivirals, H 2 -receptor antagonists, 5HT ⁇ agonists, 5HT 3 antagonists, COX2-inhibitors, medicaments used in treating psychiatric conditions such as depression, anxiety, bipolar condition, tranquilizers , medicaments used in treating metabolic conditions, anticancer medicaments, medicaments used in treating neurological conditions such as epilepsy and Parkinsons Disease, medicaments used in treating cardiovascular conditions, non-steroidal anti-inflammatory medicaments, medicaments used in treating Central Nervous System conditions, and medicaments employed in treating hepatitis.
- the term medicament also encompasses pharmaceutically acceptable salts, esters, solvates, and/or hydrates of the pharmaceutically active substances referred to hereinabove.
- an oral pharmaceutical formulation typically refers to the combination of at least one medicament and one or more added components or elements, such as an "excipient” or “carrier.”
- excipient and carrier generally refer to substantially inert materials that are nontoxic and do not interact with other components of the composition in a deleterious manner.
- excipients include pharmaceutical grades of carbohydrates, including monosaccharides, disaccharides, cyclodextrins and polysacchahdes (e.g., dextrose, sucrose, lactose, raffinose, mannitol, sorbitol, inositol, dexthns and maltodextrins); starch; cellulose; salts (e.g., sodium or calcium phosphates, calcium sulfate, magnesium sulfate); citric acid; tartaric acid; glycine; leucine; high molecular weight polyethylene glyols (PEG); pluronics; surfactants; lubricants; stearates and their salts or esters (e.g., magnesium stearate); amino acids; fatty acids; and combinations thereof.
- FIGS. 1a and 1b depict an embodiment of a packaging system 10 according to the present invention. As shown, the system 10 is present as a unitary structure and includes an outer container 20. In this embodiment, outer container 20 has a cross-sectional area 30 that is circular shaped.
- the outer container 20 includes a flange 40 and a container wall 50 extending downwardly from flange 40 and throughout the periphery of the flange 40.
- the bottom of the container wall 50 is left unclosed such that it is open to the external environment, accordingly, a void space 60 is formed within the container wall 50.
- an inner container within the void space 60, and as shown in FIG. 1a, an inner container
- the diameter of the inner container (d) may be selected from various sizes. For example, in one embodiment, the diameter may range from about 1 cm to about 10 cm.
- a first portion 80 of the inner container 70 extends below flange 40 and into the void space 60 and a second portion 90 extending above the flange 40.
- a package outsell (depicted as 65) may be present in the void space 60 formed between the inner container 70 and the outer container 20.
- the inner container 70 includes a neck 100 having a base portion 110. As depicted in FIG. 1, the flange 40 is attached to inner container 70 at base portion 110 such that the outer container 20 and the inner container 70 are joined and thus present as a unitary structure.
- FIG. 1 the diameter of the inner container 70 is present.
- FIG. 2 represents a perspective view of the packaging system 10 illustrated in cross-section in FIG. 1.
- a bottle label 120 may be present on outer surface 130 of outer container 20.
- a microelectronic chip having an antenna associated therewith shown in FIG. 5 as 140 can be attached to outer surface 130.
- FIGS. 1a, 1b, and 2 depict the cross-section of outer container 20 being circular shaped. It should be appreciated that, for the purposes of the invention, outer container may have other cross-sectional configurations including, without limitation, circular, triangular, heptagonal, hexagonal, octahedral, etc. As an example, FIGS. 3a, 3b and 4 depict the cross-section of outer container 20 being rectangular (e.g., square) shaped.
- FIG. 5 illustrates an array 10' of packaging systems 10 having square cross-sectional areas. As shown, caps 150 are present on the packaging systems 10.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/568,992 US20070209331A1 (en) | 2004-05-21 | 2005-05-16 | Medicament housing apparatus having outer and inner containers |
JP2007527335A JP2008500133A (en) | 2004-05-21 | 2005-05-16 | Drug storage device having outer container part and inner container part |
CA002566313A CA2566313A1 (en) | 2004-05-21 | 2005-05-16 | Medicament housing apparatus having outer and inner containers |
EP05749362A EP1755978A1 (en) | 2004-05-21 | 2005-05-16 | Medicament housing apparatus having outer and inner containers |
IL179034A IL179034A0 (en) | 2004-05-21 | 2006-11-02 | Medicament housing apparatus having outer and inner containers |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57345304P | 2004-05-21 | 2004-05-21 | |
US60/573,453 | 2004-05-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005115869A1 true WO2005115869A1 (en) | 2005-12-08 |
Family
ID=35450766
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/017027 WO2005115869A1 (en) | 2004-05-21 | 2005-05-16 | Medicament housing apparatus having outer and inner containers |
Country Status (6)
Country | Link |
---|---|
US (1) | US20070209331A1 (en) |
EP (1) | EP1755978A1 (en) |
JP (1) | JP2008500133A (en) |
CA (1) | CA2566313A1 (en) |
IL (1) | IL179034A0 (en) |
WO (1) | WO2005115869A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010516308A (en) * | 2007-01-20 | 2010-05-20 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Pack containing soft capsules |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4247316A1 (en) * | 2020-11-20 | 2023-09-27 | SiO2 Medical Products, Inc. | Polymer vials having standard external dimensions and reduced internal volume |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2000419A (en) * | 1934-01-18 | 1935-05-07 | Emery N Sarber | Advertising condiment shaker |
US2945314A (en) * | 1957-10-17 | 1960-07-19 | Brian E Baldwin | Display device |
US3374911A (en) * | 1967-05-15 | 1968-03-26 | Robert V. White | Plastic cosmetic jar |
US4871077A (en) * | 1987-04-27 | 1989-10-03 | Doxtech, Inc. | Tamper resistant, tamper evident leak proof container |
US20030080128A1 (en) * | 2001-10-17 | 2003-05-01 | Olcott Plastics | Method of making an improved jar container |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2493922A (en) * | 1945-02-13 | 1950-01-10 | Coeur Company | Container |
US5315811A (en) * | 1991-05-30 | 1994-05-31 | Drug Plastics & Glass Company, Inc. | Method of packaging with an outer container having a container insert for holding a predetermined volume of material |
US5197602A (en) * | 1991-05-30 | 1993-03-30 | Drug Plastics & Glass Company, Inc. | Packing system comprising a plurality of outer containers having container inserts therein for holding a predetermined volume of material |
US6243936B1 (en) * | 1991-05-30 | 2001-06-12 | Drug Plastics And Glass Company, Inc. | Method for assembling an outer container having a container insert therein for holding a predetermined volume of material |
US5318183A (en) * | 1991-09-19 | 1994-06-07 | Glaxo, Inc. | Bottle with insert to reduce effective volume |
GB9519196D0 (en) * | 1995-09-20 | 1995-11-22 | Jaycare Ltd | Improvements relating to packaging containers |
US6076697A (en) * | 1997-06-09 | 2000-06-20 | Allabaugh, Jr.; Robert Carleton | Crate for cartons |
JP4462689B2 (en) * | 2000-01-18 | 2010-05-12 | 株式会社トーショー | Chemical storage device |
US6360462B1 (en) * | 2000-04-10 | 2002-03-26 | Mcneil-Ppc, Inc. | Container with label |
US6301812B1 (en) * | 2000-09-19 | 2001-10-16 | Richard Klunk | Gift container and associated methods |
US20040045863A1 (en) * | 2002-09-06 | 2004-03-11 | Rhoades Dean L. | Container with extractable and retractable instructions |
-
2005
- 2005-05-16 US US11/568,992 patent/US20070209331A1/en not_active Abandoned
- 2005-05-16 CA CA002566313A patent/CA2566313A1/en not_active Abandoned
- 2005-05-16 EP EP05749362A patent/EP1755978A1/en not_active Withdrawn
- 2005-05-16 WO PCT/US2005/017027 patent/WO2005115869A1/en not_active Application Discontinuation
- 2005-05-16 JP JP2007527335A patent/JP2008500133A/en active Pending
-
2006
- 2006-11-02 IL IL179034A patent/IL179034A0/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2000419A (en) * | 1934-01-18 | 1935-05-07 | Emery N Sarber | Advertising condiment shaker |
US2945314A (en) * | 1957-10-17 | 1960-07-19 | Brian E Baldwin | Display device |
US3374911A (en) * | 1967-05-15 | 1968-03-26 | Robert V. White | Plastic cosmetic jar |
US4871077A (en) * | 1987-04-27 | 1989-10-03 | Doxtech, Inc. | Tamper resistant, tamper evident leak proof container |
US20030080128A1 (en) * | 2001-10-17 | 2003-05-01 | Olcott Plastics | Method of making an improved jar container |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010516308A (en) * | 2007-01-20 | 2010-05-20 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Pack containing soft capsules |
Also Published As
Publication number | Publication date |
---|---|
US20070209331A1 (en) | 2007-09-13 |
IL179034A0 (en) | 2007-03-08 |
EP1755978A1 (en) | 2007-02-28 |
CA2566313A1 (en) | 2005-12-08 |
JP2008500133A (en) | 2008-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8443977B2 (en) | Blister package apparatus and methods for tablets | |
US5318183A (en) | Bottle with insert to reduce effective volume | |
US8322567B2 (en) | Containers with pill dispensing feature | |
CA1197818A (en) | Dry pharmaceutical system | |
US20140183070A1 (en) | Device for Disposing Medicament Products | |
US5084040A (en) | Lyophilization device | |
JPH08503155A (en) | Method of freeze-drying and sealing similar to freeze-dried compound cartridge assembly forming the disposable portion of an injector pen | |
WO1995016428A1 (en) | A combination pill crushing and dispensing cup | |
SK282868B6 (en) | Biconvex rapidly disintegrating dosage forms | |
US20100183776A1 (en) | Water bottle with dosage in a blister pack | |
DE202013012689U1 (en) | Holding structure for simultaneously holding a plurality of containers for storing substances for medical, pharmaceutical or cosmetic applications as well as transport or packaging containers and combination with self | |
TWI794137B (en) | Affixed groups of pharmaceutical vials including frangible connectors | |
US10675217B2 (en) | Spherical pill container with domed lid | |
US20110147252A1 (en) | Packages and inserts useful for dispensing medicines | |
US20070209331A1 (en) | Medicament housing apparatus having outer and inner containers | |
US10912713B2 (en) | Self-standing drug-filled synthetic resin ampule | |
WO2002013762A3 (en) | Improved solid pharmaceutical dosage formulation of hydrophobic drugs | |
JPH11189280A (en) | Lid of container receiving granular substance | |
US20220265516A1 (en) | Dosing and administration system for drug combinations | |
US9731852B2 (en) | Water bottle with dosage in a blister pack | |
US20040040985A1 (en) | Medicament dispensing container closure assembly | |
WO2019113276A1 (en) | Container and method for reconstitution of substances | |
WO2005112672A1 (en) | Tablet dispenser insert for stacked tablets | |
JP2023002426A (en) | Container and discharge product | |
WO1999025629A1 (en) | Multicompartment container for combination products |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 179034 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3214/KOLNP/2006 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11568992 Country of ref document: US Ref document number: 2007209331 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2566313 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005749362 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007527335 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2005749362 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11568992 Country of ref document: US |